Most Read Articles
Lianne Cowie, 01 Nov 2013

Tumor necrosis factor (TNF)-α inhibitors are commonly used in the treatment of inflammatory bowel disease (IBD), but the effects of these agents on pregnancy outcomes remain unclear. Now, a systematic review of the English literature has indicated that they pose little risk to the mother or her infant, even if use is continued through the third trimester.

15 Jun 2017
Telomeres appear to be shorter in patients with gout than in healthy individuals, indicating increased cellular senescence, according to a study. In gout, telomere shortening is associated with flare frequency and cardiovascular (CV) disease.
16 Apr 2014

The skeleton is one of the most common sites of metastases. Metastatic tumors are the most common malignancy of bone, affecting 10 to 30 percent of cancer patients.

30 Mar 2017
Patients diagnosed with asthma are at a greater risk of schizophrenia, a new study shows. On the other hand, corticosteroid use is not tied to increased risks of schizophrenia.

Adalimumab plus MTX effective in JIA-associated uveitis

20 May 2017

Combination therapy with methotrexate (MTX) and adalimumab, a human anti–tumour necrosis factor α monoclonal antibody, is effective in the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis, according to a recent report.


In the multicentre, double-blind study, researchers assessed the efficacy and safety of adalimumab in children and adolescents ≥2 years of age who had active JIA-associated uveitis and who were receiving a stable dose of MTX. The children were randomized in a 2:1 ratio to receive subcutaneous adalimumab (20 or 40 mg based on body weight) or placebo every 2 weeks until treatment failure or until 18 months had elapsed. They were followed-up for 2 years from the time of randomization. The primary endpoint was time to treatment failure.


The trial was halted early when the prespecified stopping criteria were met after the enrolment of 90 of 114 patients. It was clear that the therapy was effective as the treatment failure rate was 27 percent among adalimumab recipients but 60 percent among those in the placebo group (hazard ratio (HR), 0.25, 95 percent confidence interval (CI) 0.12–0.49; p<0.0001 (this HR was the prespecified stopping boundary). However, the rates of adverse events (10.07 events/patient-year vs 6.51 events/patient-year) and serious adverse events (0.29 events/patient-year vs 0.19 events/patient-year) were also higher among adalimumab recipients. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Lianne Cowie, 01 Nov 2013

Tumor necrosis factor (TNF)-α inhibitors are commonly used in the treatment of inflammatory bowel disease (IBD), but the effects of these agents on pregnancy outcomes remain unclear. Now, a systematic review of the English literature has indicated that they pose little risk to the mother or her infant, even if use is continued through the third trimester.

15 Jun 2017
Telomeres appear to be shorter in patients with gout than in healthy individuals, indicating increased cellular senescence, according to a study. In gout, telomere shortening is associated with flare frequency and cardiovascular (CV) disease.
16 Apr 2014

The skeleton is one of the most common sites of metastases. Metastatic tumors are the most common malignancy of bone, affecting 10 to 30 percent of cancer patients.

30 Mar 2017
Patients diagnosed with asthma are at a greater risk of schizophrenia, a new study shows. On the other hand, corticosteroid use is not tied to increased risks of schizophrenia.